These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 8984133

  • 1. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
    Tikkanen I, Omvik P, Jensen HA.
    J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
    [Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension.
    Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS.
    Hypertension; 1995 Jun; 25(6):1345-50. PubMed ID: 7768585
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
    Ruff D, Gazdick LP, Berman R, Goldberg AI, Sweet CS.
    J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306
    [Abstract] [Full Text] [Related]

  • 4. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
    Byyny RL, Merrill DD, Bradstreet TE, Sweet CS.
    Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074
    [Abstract] [Full Text] [Related]

  • 5. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
    Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Kassler-Taub K, Osbakken M.
    J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
    [Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
    [Abstract] [Full Text] [Related]

  • 7. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.
    Townsend R, Haggert B, Liss C, Edelman JM.
    Clin Ther; 1995 Jan; 17(5):911-23. PubMed ID: 8595643
    [Abstract] [Full Text] [Related]

  • 9. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI, Dunlay MC, Sweet CS.
    Am J Cardiol; 1995 Apr 15; 75(12):793-5. PubMed ID: 7717281
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
    Lacourcière Y.
    Clin Ther; 2000 Oct 15; 22(10):1213-24. PubMed ID: 11110232
    [Abstract] [Full Text] [Related]

  • 11. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension.
    Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS.
    Blood Press; 1997 Jan 15; 6(1):35-43. PubMed ID: 9116924
    [Abstract] [Full Text] [Related]

  • 12. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
    Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F.
    J Hypertens; 1996 Sep 15; 14(9):1147-51. PubMed ID: 8986917
    [Abstract] [Full Text] [Related]

  • 13. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.
    Ruilope LM, Simpson RL, Toh J, Arcuri KE, Goldberg AI, Sweet CS.
    Blood Press; 1996 Jan 15; 5(1):32-40. PubMed ID: 8777471
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM.
    Clin Ther; 1996 Jan 15; 18(3):411-28. PubMed ID: 8829017
    [Abstract] [Full Text] [Related]

  • 15. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T, Yoshinaga K.
    Blood Press Suppl; 1996 Jan 15; 2():78-81. PubMed ID: 8913545
    [Abstract] [Full Text] [Related]

  • 16. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
    Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE.
    Nephrol Dial Transplant; 1997 Jan 15; 12 Suppl 2():19-23. PubMed ID: 9269694
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
    Dickstein K, Chang P, Willenheimer R, Haunsø S, Remes J, Hall C, Kjekshus J.
    J Am Coll Cardiol; 1995 Aug 15; 26(2):438-45. PubMed ID: 7608448
    [Abstract] [Full Text] [Related]

  • 18. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients.
    Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet C, Ménard J.
    J Hypertens; 2000 Aug 15; 18(8):1139-47. PubMed ID: 10954007
    [Abstract] [Full Text] [Related]

  • 19. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T, Effect Study Group.
    Blood Press; 2001 Aug 15; 10(1):43-51. PubMed ID: 11332334
    [Abstract] [Full Text] [Related]

  • 20. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
    Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA.
    Am J Cardiol; 1997 Dec 15; 80(12):1613-5. PubMed ID: 9416950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.